Qian Dai

Dr. Qian Dai


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
XCXin Chen
Xin Chen
YQYirui Qin
Yirui Qin
LWLijun Wang
Lijun Wang
YZYujing Zhu
Yujing Zhu
HZHailu Zhang
Hailu Zhang
QDQian Dai
Qian Dai

5 August 2025 in ACS Omega
Verified
Journal Article
Open access
XCXin Chen
Xin Chen
JDJia Deng
Jia Deng
QDQian Dai
Qian Dai
HZHailu Zhang
Hailu Zhang
Natural products are the main source of drug development and nutritional supplements due to their abundant bioactivity and guaranteed safety. Nonetheless, their journey from the laboratory to market faces formidable hurdles, primarily stemming from issues such as poor solubility and limited bioavailability. To combat these hurdles, coamorphous (CAM) technology has emerged as a recent solution, offering advantages in solubility enhancement, stability, drug loading capacity, and combination with other drugs. Coamorphization of natural active pharmaceutical ingredients (APIs) holds promise for enhancing their druggability and presents an opportunity for combining them with synthetic drugs. This review encapsulates recent advancements in natural API CAM systems, covering their preparation and characterization techniques and diverse applications, summarizing reported systems, and offering an outlook on future possibilities and perspectives.

22 August 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
DSDianze Song
Dianze Song
XZXiaoqin Zhou
Xiaoqin Zhou
QYQingqing Yu
Qingqing Yu
RLRenjie Li
Renjie Li
QDQian Dai
Qian Dai
MZMei Zeng
Mei Zeng
Activation of the NLRP3 inflammasome is critical in the inflammatory response to gout. Potassium ion (K+) efflux mediated by the TWIK2 channel is an important upstream mechanism for NLRP3 inflammasome activation. Therefore, the TWIK2 channel may be a promising therapeutic target for MSU crystal-induced inflammation. In the present study, we investigated the effect of ML335, a known K2P channel modulator, on MSU crystal-induced inflammatory responses and its underlying molecular mechanisms. By molecular docking, we calculated the binding energies and inhibition constants of five K2P channel modulators (Hydroxychloroquine, Fluoxetine, DCPIB, ML365 and ML335) with TWIK2. Intracellular potassium ion concentration and mitochondrial function were assessed by flow cytometry. The interaction between MARCH5 and SIRT3 was demonstrated by immunoprecipitation and Western blotting assay. MSU suspensions were injected into mouse paw and peritoneal cavity to induce acute gout model. ML335 has the highest binding energy and the lowest inhibition constant with TWIK2 in the five calculated K2P channel modulators. In comparison, among these five compounds, ML335 efficiently inhibited the release of IL-1β from MSU crystal-treated BMDMs. ML335 decreased MSU crystal-induced K+ efflux mainly dependent on TWIK2 channel. More importantly, ML335 can effectively inhibit the expression of the mitochondrial E3 ubiquitin ligase MARCH5 induced by MSU crystals, and MARCH5 can interact with the SIRT3 protein. ML335 blocked MSU crystal-induced ubiquitination of SIRT3 protein by MARCH5. In addition, ML335 improved mitochondrial dynamics homeostasis and mitochondrial function by inhibiting MARCH5 protein expression. ML335 attenuated the inflammatory response induced by MSU crystals in vivo and in vitro. Inhibition of TWIK2-mediated K+ efflux by ML335 alleviated mitochondrial injury via suppressing March5 expression, suggesting that ML335 may be an effective candidate for the future treatment of gout.

22 August 2025 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
QYQingqing Yu
Qingqing Yu
RLRenjie Li
Renjie Li
GYGuizhao Yang
Guizhao Yang
YXYan Xiao
Yan Xiao
XLXingyu Liu
Xingyu Liu
MZMei Zeng
Mei Zeng
The mitochondrial calcium uniporter (MCU) is the key channel regulating mitochondrial calcium (Ca²⁺) uptake. Growing evidence indicates that mitochondrial Ca²⁺ homeostasis plays a pivotal role in regulating immune cell function. However, how MCU contributes to MSU crystal-driven inflammation and its molecular mechanisms are unclear. Using bone marrow-derived macrophages (BMDMs), wild-type (WT, MCU⁺/⁺), and MCU knockout (MCU⁻/⁻) mice, we investigated the role of MCU in MSU crystal-induced inflammation. Co-immunoprecipitation assays were employed to examine interactions among MCU, SIRT5, and TRIM21. MSU crystals stimulation up-regulated MCU expression and triggered mitochondrial Ca²⁺ overload in macrophages. MCU deficiency reduced mitochondrial Ca²⁺ accumulation, ameliorated mitochondrial dysfunction, and suppressed NLRP3 inflammasome activation in BMDMs treated with MSU crystals. Mechanistically, MCU promoted TRIM21 expression, leading to SIRT5 ubiquitination and degradation. Furthermore, MCU facilitated the interaction between TRIM21 and SIRT5, with MSU crystals enhancing this tripartite association. TRIM21 and SIRT5 were identified as key downstream effectors of MCU, mediating MSU crystal-induced inflammatory responses and oxidative stress. In vivo, MCU deficient mice exhibited diminished immune cell infiltration and IL-1β production in MSU crystal-induced peritonitis and arthritis models. Our findings demonstrate that MCU drives mitochondrial Ca²⁺ overload in MSU crystal-induced inflammation and promotes SIRT5 degradation via the TRIM21-SIRT5 signaling axis. These insights highlight MCU as a potential therapeutic target in gouty inflammation.

18 August 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
SXShusen Xia
Shusen Xia
LLLixin Liu
Lixin Liu
YZYi Zhou
Yi Zhou
YZYanbin Zhu
Yanbin Zhu
QDQian Dai
Qian Dai
HPHong Peng
Hong Peng
Recent research has highlighted ctDNA as a crucial tool for screening, monitoring, and treating colorectal cancer, gaining significant attention. This study aims to map the research landscape via bibliometric analysis, identifying future trends and key areas of interest. We collected articles and reviews on ctDNA and colorectal cancer from the Web of Science Core Collection and Scopus, conducting bibliometric analysis and visualization using VOSviewer, CiteSpace, and R packages. A total of 1,730 publications were included in the bibliometric analysis. Of these, 325 were unique to WOS and 639 were unique to SCOPUS. The United States and China led in publication volume with 555 and 306 papers, respectively, while the United States and Italy had the highest citation counts, with 39,142 and 21,417 citations, respectively. The University of Texas MD Anderson Cancer Center was the most prolific institution. The journals Cancers and Frontiers in Oncology were the most frequently published. Bardelli A stood out as the most prolific and cited author. Cluster analysis revealed trending topics such as “minimal residual disease,” “adjuvant chemotherapy,” and “recurrence.” This bibliometric analysis highlights significant advancements and emerging trends in the clinical application of ctDNA for colorectal cancer. The identified hotspots deserve further attention from researchers in this field.

16 April 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
YLYaoYun Liang
YaoYun Liang
XTXinYu Tan
XinYu Tan
QDQian Dai
Qian Dai
JLJianping Liu
Jianping Liu
Objective: This study utilized FDA Adverse Event Reporting System (FAERS) data and network pharmacology methods to evaluate the risk of renal adverse events (AEs) associated with calcineurin inhibitors (CNIs), providing guidance for safe drug use. Method: By analyzing FAERS data from 2004 to 2024, we identified renal AEs associated with CNI therapy. We employed imbalance analysis (report odds ratio [ROR], proportion of reports ratio [PRR], MGPS, and Bayesian confidence propagation neural network [BCPNN]) to detect signals and explored drug-gene interaction networks to investigate potential mechanisms. Results: Revealed significant associations between cyclosporine, tacrolimus, and voclosporin with renal injury, with voclosporin showing stronger correlations (ROR = 5.24, PRR = 4.85, EBGM05 = 4.85, IC025 = 2.28) but lower mortality rates. Network pharmacology analysis suggested that cyclosporine, tacrolimus, and everolimus may exert their toxic effects by acting on core genes. Conclusion: The widespread use of CNIs raises concerns about their renal safety. This study provides new evidence from real-world data indicating differences in renal toxicity risk and mechanisms among calcineurin inhibitors (CNIs), underscoring the importance of pharmacovigilance strategies for patients with autoimmune diseases.